Bristol-Myers Squibb in April quit making injected Coumadin, the form used in the rare cases when patients can't take the oral formulation. But there is still product in the market and and the company is having to recall some of it.
Bristol-Myers Squibb has tapped Duke University's in-house CRO to pitch in on clinical trial transparency, asking the organization's researchers to independently review requests for shared data.
While the debate over how to implement clinical trial data transparency laws rages in Europe, Big Pharma firms continue to roll out their own offerings, with Bristol-Myers Squibb the latest to show its hand. And the U.S. drugmaker has gone further than some of its peers by handing over decision-making powers to a third party and promising to publish full clinical study reports.
Right now, Eliquis, the new-age clot-fighter from Pfizer and Bristol-Myers Squibb, is in third place in a three-horse race. But as it tries to catch up to rivals Pradaxa and Xarelto--not to mention the $3-billion-per-year sales forecasts analysts slapped on it in its early days--a new recommendation for expanded use in Europe should give it a boost.
European regulators are recommending approval for Bristol-Myers Squibb's daclatasvir, an hepatitis C-fighting antiviral that plays a key role in the company's planned combo treatment.
Avista Capital Partners is looking for liquidity in its investment in medical imaging agent provider Lantheus. The company recently filed for a $125 million IPO. The financing would allow Lantheus to repay some of the debt that the private equity firm loaded it up with, in part to pay itself dividends.
Bristol-Myers Squibb claimed bragging rights to the first batch of Phase III data on an immuno-oncology drug that clearly demonstrated an improvement over a standard therapy for overall survival.
Gilead Sciences' Sovaldi has broken sales records thanks to its ability to cure hepatitis C with an effective, if costly, 12-week regimen. But rivals believe there's plenty of room in the market for a speedier solution, and Bristol-Myers Squibb plans to use its ex-partner's blockbuster to craft a four-week contender.
Three months after Britain's National Institute for Health and Care Excellence said it would not recommend Bristol-Myers Squibb's Yervoy as a first-line treatment for melanoma, the much-feared cost-effectiveness agency has changed its mind. A new draft guidance from NICE now says Yervoy should be available as the first choice for treating patients with advanced melanoma.
Bristol-Myers Squibb's pioneering early-stage study of a combination of Yervoy and its PD-1 drug nivolumab has posted extended survival data showing that a large majority of patients taking the optimum dose now in late-stage trials survived to the two-year mark. The new figures from a leader in the field underscore a steadily broadening portfolio of data that demonstrates these immuno-oncology drugs offer a new method for guarding cancer patients' lives.